Are you interested in optimizing your treatment? In 'Optimizing GIST Treatment', this world-renown GIST expert from Europe will share his wealth of experience and insight about how he has helped patients live longer, and [...]
The time it takes between the appearance of first symptoms of a rare disease and when the correct diagnosis is given, is often years if not decades instead of days or weeks like it is [...]
Some stomach GISTs smaller than 2 cm may pose more risk than previously thought according to a new report from China.
Having your GISTory or medical summary up to date and handy when faced with a medical emergency, is crucial to have on hand, when making decisions on how to proceed with your care.
Adrian Mariño-Enriquez explains the significance of a recently published study that will have a big impact on GIST research. Keep reading to learn the critical role of CDC37 in GIST tumors.
Ovarian cancer treatment flaws have been exposed during a recent study, according to an article in the New York Times. The study was conducted by Dr. Robert E. Bristow, director of gynecologic oncology at the University of California, Irvine.
Here is a presentation from Life Fest 2012 by Brian Rubin, M.D. about the current state of the LRG Research team.
Here is a presentation from Life Fest 2012 by Roberto Pazmino on the Life Raft Group Patient Registry.
Pfizer Pharmaceuticals is offering Sutent in Touch, a program to support GIST patients on its drug Sutent. The program is free and patients can sign up by calling (1-877-578-8368). Sutent in Touch links patients to Oncology [...]
Bayer recently announced the results of its Phase III trial for regorafenib (BAY 73-4506), which is designed for patients with metastatic and/or unresectable GIST that have failed both imatinib and sunitinib.